Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial

Sophia Zoungas, Barry Patrick McGrath, Pauline Branley, Peter Kerr, Christine Muske, Rory S Wolfe, Robert Charles Atkins, Kathy Nicholls, Margaret Fraenkel, Brian G Hutchison, Robert Walker, John James McNeil

Research output: Contribution to journalArticleResearchpeer-review

202 Citations (Scopus)


The Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) aimed to establish whether high-dose folic acid would slow the progression of atherosclerosis and reduce cardiovascular events in patients with chronic renal failure (CRF).
Original languageEnglish
Pages (from-to)1108 - 1116
Number of pages9
JournalJournal of the American College of Cardiology
Issue number6
Publication statusPublished - 2006

Cite this